Skip to main content

Advertisement

Table 3 Association of MMP-9 mRNA levels with pathology/clinical characteristics of the study participants

From: The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer

Variables Mean ± SD Percentiles P value
25th 50th (Median) 75th
Patients
 MNG 2.49 ± 3.70 0.17 0.70 3.40 0.001
 PTC 6.77 ± 7.16 1.22 3.83 10.50
PTC patients analysis
 Tissues of PTC patients
  Adjacent non-tumoral 3.06 ± 3.63 0.32 1.68 4.35 0.039
  Tumoral 8.05 ± 16.48 1.07 2.77 6.07
 Age
  < 45 years 1.83 ± 2.13 0.25 0.91 2.86 0.015
  ≥45 years 6.59 ± 13.01 0.92 2.42 6.08
 Sex
  Male 1.47 ± 1.49 0.40 0.85 2.80 0.993
  Female 4.51 ± 10.71 0.23 0.96 2.51
 BRAF V600E mutation
  BRAF (+) 1.66 ± 1.69 0.28 1.25 2.45 0.987
  BRAF (−) 4.14 ± 12.59 0.31 0.80 3.64
 Tumor size
  < 2 cm 1.65 ± 1.68 0.35 1.18 2.46 0.960
  ≥2 cm 5.15 ± 14.82 0.23 0.77 2.81
 TNM Staging
  I/II 1.80 ± 1.98 0.28 0.89 2.82 0.011
  III/IV 9.23 ± 15.80 1.32 5.53 7.78
 Focality Status
  Unifocal 1.76 ± 1.44 0.43 1.42 3.48 0.481
  Multifocality 2.27 ± 5.08 0.30 0.84 1.93
 Extracapsular invasion
  Yes 10.60 ± 22.88 0.55 1.71 4.34 0.354
  No 2.06 ± 2.16 0.28 1.35 3.55
 LNM
  Yes 2.82 ± 6.18 0.35 1.08 3.12 0.413
  No 1.28 ± 1.27 0.18 0.70 2.12
 Lymphovascular invasion
  Yes 4.52 ± 0.82 3.65 4.81 5.10 0.003
  No 1.65 ± 1.60 0.40 1.08 2.70
  1. PTC papillary thyroid carcinoma, MNG multinodular goiter, TNM tumor node metastasis, SD standard deviation, LNM lymph node metastasis, P value is for median of MMP-9 expression